Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Rivian enters its Q3 results window on October 27 with a deteriorating price chart, a short book that has been quietly rebuilding, and a set of real-economy signals that offer little comfort on near-term demand.
The stock closed Friday at $14.30, down 7.6% on the week and 7.9% over the past month. That puts it within touching distance of Morgan Stanley's Underweight target of $14, the lowest formal target on the Street. The week's decline outpaced the broader EV peer group. XPEV dropped 8.6%, broadly in line. TSLA fell less than 1% over the same five sessions, widening the gap between Rivian and the category leader.
Short positioning is the clearest pressure point heading into earnings. At 12.7% of the free float, short interest is already elevated, and it has been edging higher. Shares short rose about 0.5% over the past week and roughly 1% over the past month. The move back above the 155 million share level follows a notable step-down in late September, when SI briefly retreated toward 154 million before reversing. Borrow costs remain low at 0.56%, rising only modestly over the past month, so shorts are not under meaningful financial pressure to close. Availability has tightened from over 250% in late August to around 177% now, meaning the lending pool is less loose than it was six weeks ago, though at 177% it is far from distressed. The options market is similarly unhelpful as a squeeze signal. The put/call ratio at 0.94 is almost exactly in line with its 20-day average of 0.94, a z-score of essentially zero. Options traders are neither notably bearish nor positioned for a sharp reversal. The ORTEX short score has drifted to 68.7, its highest reading in the 10-day window shown, and ranks in just the 7th percentile of all stocks on the short-score factor, reflecting how persistently elevated the bearish positioning has been.
The Street is divided but tilts cautious. Citigroup initiated coverage on September 14 at Neutral with an $18 target, the most recent analyst action within the past three weeks. Earlier activity, clustered around the July 31 results, saw Morgan Stanley reiterate Underweight at $14, while TD Cowen maintained Buy at $21 and Needham held at $23. The consensus mean target sits at $19.23, implying roughly 34% upside to Friday's close, but that gap reflects disagreement rather than conviction. EPS momentum factor scores are in the 9th percentile on both the 30-day and 90-day windows, a signal that estimate revisions have been running against the stock. The price-to-book multiple at 5.9x has compressed about 5% over the past 30 days. The bear case centres on an execution-heavy ramp across competing EV segments, a negative adjusted EBITDA outlook of roughly $2 billion for 2026, and the risk of further equity dilution. The bull case leans on the R2 launch in H1 2026, the Amazon EDV fleet relationship, the Volkswagen partnership, and a software and autonomy roadmap that could eventually add a higher-margin revenue layer.
The alt data on Rivian's own registration footprint tells a cautionary story. California ZEV sales by make fell 42% year-on-year in Q2 and have declined for three consecutive quarters, based on California Energy Commission data. In Washington State, August recorded the smallest new battery-electric registration count since 2022 data began. Colorado shows 18 consecutive months of growth in total registered battery-electric vehicles per Atlas EV Hub data, but that is a fleet figure across all brands, not Rivian-specific. None of the alt data datasets covering Rivian have been measured to lead its reported figures, so these readings are real-economy colour rather than a signal on the Q3 print. Dutch registration data from RDW has not yet accumulated enough history to be tested. What the data does illustrate is that the pocket of the EV market most relevant to Rivian's truck and SUV products has been under pressure in the largest US state market for three straight quarters.
On the ownership register, Volkswagen's stake sits at 15.9%, up from 12.3% at the prior filing per the Schedule 13G/A from May 2026, and there are no active 13D filings. Insider activity over the past 90 days has been modest and entirely pre-planned: the Chief Administrative Officer sold $225,000 in a 10b5-1 plan in early October, and the CFO made two small scheduled sales in August. Net insider selling over the 90-day window totals about $1.2 million in value, all under standing trading plans, carrying little discretionary signal.
With the Q3 print 22 days away, the October 27 call becomes the fulcrum. Rivian fell 6.8% the day after Q2 results in late July, and the five-day move after that print was minus 5.8%, so the stock has established a pattern of selling off in the days following earnings. What will matter most on October 27 is whether production and delivery numbers come in ahead of the trajectory implied by the California and Washington registration data, and whether management provides any update on the R2 launch timing and per-vehicle cost progress.
See the live data behind this article on ORTEX.
Open RIVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.